18 Dec 2023
Report on the Collection of Under Co-payment Data 2022-23
Report on the Collection of Under Co-payment Data 2022-23
15 Dec 2023
Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – November 2023
Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – November 2023
11 Dec 2023
PBS subsidy arrangements for fluoxetine SSSI
PBS subsidy arrangements for fluoxetine SSSI
08 Dec 2023
PBS reason codes 162/163 when dispensing biosimilar brands
PBS reason codes 162/163 when dispensing biosimilar brands
08 Dec 2023
Updates to the HTA Policy and Methods Review Reference Committee – 8 December 2023
Updates to the HTA Policy and Methods Review Reference Committee – 8 December 2023
01 Dec 2023
Updates to the HTA Policy and Methods Review Reference Committee – 1 December 2023
To ensure that the Reference Committee has sufficient time to consider the extensive and valuable input and material received for the HTA Review so far, as well as conduct further public consultation, the HTA Review has been extended until 15 April 2024.
01 Dec 2023
PBS Safety Net early supply for 60-day prescriptions
PBS Safety Net early supply for 60-day prescriptions
01 Dec 2023
PBS arrangements due to discontinuation of the Ordine brands of morphine hydrochloride trihydrate oral liquids effective 1 December 2023
Two new temporarily PBS listings for morphine sulfate will be effective from 1 December 2023. These new products are being listed to address the deletion from the Australian market of morphine hydrochloride trihydrate oral liquids (brand: Ordine).
01 Dec 2023
1 December 2023 Changes to the PBS Listings of Medicines for the Treatment of Ankylosing Spondylitis
On 1 December 2023, changes will be made to the authority requirements of the following biological medicines listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of ankylosing spondylitis – adalimumab, etanercept and infliximab.
